고혈압과 고중성지방혈증을 가진 환자에서 혈중 Fenofibrate의 Creatinine 농도에 대한 효과open accessEffect of Fenofibrate Therapy on blood creatinine levels in patients with hypertension and hypertriglyceridemia
- Authors
- 조주환; 최영환; 현철원; 김경준; 현성업; 권지은; 김은영; 이왕수; 이광제; 김상욱; 김태호; 김치정
- Issue Date
- Jun-2013
- Publisher
- 한국지질동맥경화학회
- Citation
- 지질·동맥경화학회지, v.2, no.1, pp 19 - 26
- Pages
- 8
- Journal Title
- 지질·동맥경화학회지
- Volume
- 2
- Number
- 1
- Start Page
- 19
- End Page
- 26
- URI
- https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/67495
- DOI
- 10.12997/jla.2013.2.1.19
- ISSN
- 2287-2892
2288-2561
- Abstract
- Objective:Previous studies have reported that fenofibrate therapy increased blood creatinine levels. We investigated the effect of fenofibrate therapy on creatinine levels in patients with hypertension and hypertriglyceridemia. Methods:This retrospective study included 36 hypertensive patients with hypertriglyceridemia taking fenofibrate for 1-3 years (Fenofibrate group) and 36 control patients with similar age, sex, follow-up duration, creatinine levels, and lipid levels to those of fenofibrate therapy (Control group). Results:Baseline parameters except lipid profiles were similar between the fenofibrate and control groups. Creatinine levels increased in the fenofibrate group (from 0.90±0.18 mg/dL to 1.05±0.22 mg/dL, p<0.001) and did not change in the control group (from 0.91±0.12 mg/dL to 0.92±0.14 mg/dL, p=0.39). The elevation was more pronounced in the fenofibrate group than in the control group (0.15±0.12 vs. 0.02±0.11 mg/dL, p<0.001). Changes in creatinine levels were only associated with fenofibrate therapy (r=0.52, p<0.001) in the stepwise linear regression analysis. Conclusion:Fenofibrate therapy for 1-3 years significantly increased creatinine levels in hypertensive patients with hypertriglyceridemia. This finding suggests that follow-up measurement of creatinine level is necessary with fenofibrate therapy.
- Files in This Item
-
- Appears in
Collections - ETC > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.